DK1399142T3 - Anvendelse af acetyl-L-carnitin i kombination med biotin til behandlingen af patienter med type-2 insulinresistent diabetes mellitus - Google Patents

Anvendelse af acetyl-L-carnitin i kombination med biotin til behandlingen af patienter med type-2 insulinresistent diabetes mellitus

Info

Publication number
DK1399142T3
DK1399142T3 DK02741155T DK02741155T DK1399142T3 DK 1399142 T3 DK1399142 T3 DK 1399142T3 DK 02741155 T DK02741155 T DK 02741155T DK 02741155 T DK02741155 T DK 02741155T DK 1399142 T3 DK1399142 T3 DK 1399142T3
Authority
DK
Denmark
Prior art keywords
carnitine
biotin
insulin
acetyl
patients
Prior art date
Application number
DK02741155T
Other languages
Danish (da)
English (en)
Inventor
Menotti Calvani
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Application granted granted Critical
Publication of DK1399142T3 publication Critical patent/DK1399142T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK02741155T 2001-05-29 2002-05-24 Anvendelse af acetyl-L-carnitin i kombination med biotin til behandlingen af patienter med type-2 insulinresistent diabetes mellitus DK1399142T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2001RM000294A ITRM20010294A1 (it) 2001-05-29 2001-05-29 Uso della acetil l-carnetina in associazione con la biotina per il trattamento di pazienti affetti da diabete mellito di tipo ii insulino re

Publications (1)

Publication Number Publication Date
DK1399142T3 true DK1399142T3 (da) 2006-10-30

Family

ID=11455558

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02741155T DK1399142T3 (da) 2001-05-29 2002-05-24 Anvendelse af acetyl-L-carnitin i kombination med biotin til behandlingen af patienter med type-2 insulinresistent diabetes mellitus

Country Status (18)

Country Link
US (2) US20040142879A1 (it)
EP (1) EP1399142B1 (it)
JP (1) JP4381685B2 (it)
KR (1) KR20040010666A (it)
AT (1) ATE333274T1 (it)
CA (1) CA2448244C (it)
CY (1) CY1105403T1 (it)
CZ (1) CZ297743B6 (it)
DE (1) DE60213237T2 (it)
DK (1) DK1399142T3 (it)
ES (1) ES2268053T3 (it)
HU (1) HUP0400060A2 (it)
IT (1) ITRM20010294A1 (it)
MX (1) MXPA03010921A (it)
PL (1) PL207522B1 (it)
PT (1) PT1399142E (it)
SK (1) SK287832B6 (it)
WO (1) WO2002096410A1 (it)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1341813B1 (en) * 2000-12-15 2006-09-13 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Use of l-carnitine as stabilizing agent of proteins
ITRM20040327A1 (it) * 2004-07-01 2004-10-01 Sigma Tau Ind Farmaceuti Uso della acetil l-carnitina per la preparazione di un medicamento per il trattamento del dolore neuropatico in pazienti diabetici.
US8569366B2 (en) 2005-04-26 2013-10-29 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Acetyl L-carnitine for prevention of painful peripheral neuropathy in patients with type 2 diabetes
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
CN101663030B (zh) * 2007-03-21 2013-08-21 希格马托制药工业公司 可用于预防患有胰岛素耐受的前驱糖尿病患者的2型糖尿病及其并发症的组合物
GB201304112D0 (en) * 2013-03-07 2013-04-24 Univ Nottingham Modulation of energy expenditure

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1196564B (it) * 1986-08-04 1988-11-16 Sigma Tau Ind Farmaceuti Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche
IT1263004B (it) * 1992-10-08 1996-07-23 Sigma Tau Ind Farmaceuti Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
US6020139A (en) * 1995-04-25 2000-02-01 Oridigm Corporation S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
US5789401A (en) * 1997-08-08 1998-08-04 Nutrition 21 High-dose chromium/biotin treatment of type II diabetes

Also Published As

Publication number Publication date
SK287832B6 (sk) 2011-11-04
CZ20033221A3 (cs) 2004-06-16
US8053472B2 (en) 2011-11-08
PT1399142E (pt) 2006-10-31
MXPA03010921A (es) 2004-02-27
PL207522B1 (pl) 2010-12-31
SK15852003A3 (sk) 2004-04-06
US20080269307A1 (en) 2008-10-30
CA2448244C (en) 2010-11-02
DE60213237T2 (de) 2007-08-02
ATE333274T1 (de) 2006-08-15
US20040142879A1 (en) 2004-07-22
CA2448244A1 (en) 2002-12-05
ITRM20010294A0 (it) 2001-05-29
JP4381685B2 (ja) 2009-12-09
EP1399142A1 (en) 2004-03-24
JP2004532866A (ja) 2004-10-28
DE60213237D1 (de) 2006-08-31
KR20040010666A (ko) 2004-01-31
CZ297743B6 (cs) 2007-03-21
HUP0400060A2 (hu) 2004-04-28
CY1105403T1 (el) 2010-04-28
EP1399142B1 (en) 2006-07-19
ITRM20010294A1 (it) 2002-11-29
PL367630A1 (en) 2005-03-07
WO2002096410A1 (en) 2002-12-05
ES2268053T3 (es) 2007-03-16

Similar Documents

Publication Publication Date Title
DK1599468T3 (da) 1,2,3-trisubstituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser forbundet dermed såsom diabetes og hyperglykæmi
IS2517B (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
IS7814A (is) Fenetanólamín afleiða í meðhöndlun á öndunarfærasjúkdómum.
DK1562932T3 (da) 4 tetrazolyl-4-phenylpiperidinderivater til behandling af smerter
HN2002000275A (es) Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados
WO2002036562A3 (en) 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
EA200601747A1 (ru) Три(цикло)замещённые амидные соединения
BR0112519A (pt) Derivados anticonvulsivantes úteis para prevenir o desenvolvimento de diabetes melito do tipo ii e sìndrome x
CY1108808T1 (el) Ενωσεις μοτιλιδης
BR0211972A (pt) Composição oftálmica
EA200300716A1 (ru) Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6
UY27244A1 (es) Uso del acido- (4´-trifluormetilfenil) - amida (z) -2- ciano-3- hidroxi-but-2-enoico para el tratamiento de la esclerosis multiple
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
NO20045554L (no) Fremgangsmate for behandling av diabetes
DE60228722D1 (de) Zusammensetzung und ihre verwendungszwecke zur bekämpfung von kater
CL2003002293A1 (es) Compuestos derivados de indazol; su composicion farmaceutica; su uso en el tratamiento de hipertension ocular.
CY1105403T1 (el) Χρηση της ακετυλο-l-καρνιτινης σε συνδυασμο με τη βιοτινη για τη θepαπεια ασθενων με ινσουλινο-ανθεκτικο σακχαρωδη διαβητη τυπου 2
RS8504A (en) Novel cyclohexil sulphones
ATE449066T1 (de) Biguanidderivate
SE0200198D0 (sv) New use
NO20025303L (no) Anvendelse av substituerte akryloyl-distamycin-derivater i behandlingen avtumorer assosiert med höye nivåer av glutation
DK1450782T3 (da) Anvendelse af et kombinationspræparat, der omfatter propionyl-L-carnitin og yderligere lægemidler, til behandling af erektil dysfunktion
ITRM20030178A1 (it) Uso della l-carnitina per il trattamento di patologie cardiovascolari.
ITMI20030827A1 (it) Composizione farmaceutica contenente l'associazione levodopa/carbidopa.